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Autologous hematopoietic cell transplantation (AHCT) is an established therapy for multiple myeloma (MM),
with an impact on quality of remission and survival. We analyzed the role of race, ethnicity, sex, and age
disparities in AHCT utilization in the United States. We combined MM incidence derived from the Surveil-
lance, Epidemiology and End Results program with transplantation activity reported to the Center for
International Blood and Marrow Transplant Research for the period of 2005 to 2009 to assess the impact of
disparities in AHCT. Utilization (number of transplantations/new cases) was compared between groups using
the relative utilization ratio (RUR), deﬁned as [utilization for a given category]/[utilization for the entire
population]. Data were obtained from 22,462 actual MM cases and 13,311 AHCT. The age-adjusted RUR was
1.17 (95% conﬁdence interval [CI], 1.15 to 1.19) among non-Hispanic Whites (NHW), higher than in non-
Hispanic Blacks (NHB) (age-adjusted RUR, .69; 95% CI, .67 to .72; P < .0002), Hispanics (age-adjusted RUR,
.64; 95% CI, .60 to .69; P < .002), and Asians (age-adjusted RUR, .65; 95% CI, .58 to .73; P < .0002]. AHCT
utilization was higher in men than in women among Hispanics (age-adjusted RUR .72 versus .56, P ¼ .007),
but not among NHW, NHB, or Asians. Sex disparity prevents 1.3% of potential AHCTs in patients with MM
(10.4% among Hispanics). Racial-ethnic disparities prevent 13.8% of AHCTs (44.7% in Hispanic and Asians,
39.9% in NHBs). Race-ethnicity disparity greatly affects AHCT utilization in MM. Sex disparity plays a lesser
role, except among Hispanics. The ongoing decrease in age disparity will continue to drive major increase of
AHCT activity. Two-year and 5-year increases in the age of the AHCT population would result in 12% and 32%
increases, respectively, in volume of AHCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autologous hematopoietic cell transplantation (AHCT) is
an established modality in the upfront treatment of patients
with multiple myeloma (MM). When employed early in the
management of MM in younger patients, AHCT prolongs both
the depth and duration of response and, in some studies,
overall survival [1,2]. At the population level, the expansion in
use of AHCT for management of MM over the last 2 decades
has also been linked to improved survival [3-5].
Recently, the feasibility and low toxicity of AHCT have been
demonstrated in older patients, with toxicity and disease
control comparable to younger patients [6,7]. Similarly, Black
patients undergoing AHCT for MM have outcomes similar todgments on page 705.
requests: Luciano J. Costa, MD, PhD,
-CCC, 1802 6th Avenue South, Birming-
.edu (L.J. Costa).
14.12.024
ty for Blood and Marrow Transplantation.theirWhite counterparts [8] but they are less likely to undergo
this treatment [9,10]. Little is known about transplantation
utilization in Hispanics and Asians in the United States.
We recently published a report on the increasing but yet
low utilization of AHCT among MM patients in the United
States [11]. Here, we combine MM incidence information
from Surveillance, Epidemiology and End Results (SEER)
database with the proﬁle of patients with MM undergoing
AHCT reported to the Center for International Blood and
Marrow Transplant Research (CIBMTR) during the same
period to understand how race, sex, and age can affect uti-
lization of AHCT and how correction of disparities could
affect transplantation activity.
METHODS
Data Sources
We estimated the number of new MM cases utilizing the National
Cancer Institute’s SEER registry. The SEER-18 includes the Atlanta, Con-
necticut, Detroit, Hawaii, Iowa, NewMexico, San Francisco-Oakland, Seattle-
Puget Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, Alaska
Table 1
Age Distribution of the MM and AHCT Cases according to Race/Ethnicity
Gender NHW NHB Hispanic Asian
MM cases 72.0% 18.7% 6.7% 2.6%
Male 55.6% 70 (61-78) 65 (57-74) 65 (55-74) 69 (60-77)
Female 44.4% 72 (62-81) 67 (57-76) 66 (56-76) 70 (59-78)
AHCT 77.4% 15.8% 5.2% 1.6%
Male 58.5% 60 (53-65) 58 (51-64) 56 (49-62) 57 (52-62)
Female 41.5% 59 (53-65) 57 (50-62) 57 (48-62) 58 (50-65)
Age expressed in median (interquartile range).
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Georgia tumor registries. It covers 27.8% of the US population and the rep-
resentation of each racial and ethnic group is known [12]. To estimate the
number of newMM cases (International Classiﬁcation of Diseases 3 9732/3)
diagnosed in the United States during the period of study (2005 to 2009), we
inquired the database using the case listing function of SEER*Stat8.1.5. For
each case, we extracted age, sex, race, and ethnicity (Hispanic, non-
Hispanic). We excluded cases for which the only source of information
was a death certiﬁcate or autopsy report. By knowing the number of newly
diagnosed MM cases for each racial and ethnic category (REC) and the cat-
egory’s proportional representation in the database, we were able to esti-
mate the approximate number of newMM cases in the entire US population.
Cases were grouped in 4 RECs: non-Hispanic Whites (NHW), non-Hispanic
Blacks (NHB), Hispanics (regardless of race), and Asians. Cases with un-
known race or ethnicity were excluded. Another racial group, American
Indian/Alaska Native, was not included in the analysis as it accounted for
only .2% of the MM cases and .3% of the AHCT.
We obtained the approximate number of AHCT forMM and basic patient
demographics using data from the CIBMTR. The CIBMTR is the research
afﬁliation of the International Bone Marrow Transplant Registry and the
National Marrow Donor Program. Established in 2004, it receives data from
>500 transplantation centers worldwide on allogeneic and autologous he-
matopoietic progenitor cell transplantations. Data are submitted to the
statistical center at the Medical College of Wisconsin in Milwaukee and the
National Marrow Donor Program coordinating center in Minneapolis, where
computerized checks for discrepancies, physicians’ review of submitted
data, and on-site audits of participating centers ensure data quality. In this
analysis, we utilized data regarding recipients of ﬁrst AHCT for MM in the
United States between 2005 and 2009. The information required consisted
of age, sex, race, and ethnicity andwas obtained from the pretransplantation
essential data form. The CIBMTR does not capture the totality, but instead a
known proportion of autologous transplantation events in the United States,
(methodology described elsewhere [13]). Therefore, by multiplying the
number of registered transplantations by a correction factor, one can arrive
at the approximate number of transplantations for the group of interest. For
the purpose of the present work, it was assumed that there was no age, sex,
race, or ethnicity bias in reporting AHCT procedures.
For residents of the United States, the pretransplantation essential data
form allows selection of ethnicity (Hispanic of Latino, not Hispanic, or un-
known) and race (White, Black, or African American, Asian, American Indian
or Alaska Native, Native Hawaiian, or other Paciﬁc Islander). Contrary to as in
SEER, individuals can be identiﬁed bymore than 1 race. Patients were placed
in RECs as described above for SEER. There were 3.2% of AHCT cases iden-
tiﬁed as “others,” reﬂecting mostly situations where more than 1 race or no
race was selected. These cases were distributed into the main RECs in pro-
portion to the number of registered cases for a given age. To ensure that this
reassignment did not produce false ﬁndings, we performed sensitivity
analysis with 2 other scenarios: exclusion of all AHCT with “others” iden-
tiﬁed as REC and distribution of the “others” into the 4 main categories,
proportional to the number of cases for a given age, doubling the weight of
the Hispanic and Asian categories. None of these scenarios altered the
ﬁndings of this analysis.Table 2
RUR for AHCT in MM according to Sex and Race/Ethnicity
Unadjusted RUR
REC Men Women P
NHW 1.13 (1.11-1.15) 1.02 (.99-1.04) .02
NHB .87 (.83-.92) .82 (.78-.87) .11
Hispanic .90 (.83-.97) .67 (.60-.74) <.0002
Asian .67 (.57-.77) .60 (.49-.69) .35
All 1.05 (1.03-1.07) .93 (.91-.95) <.0002Utilization
We assessed utilization as the ratio between ﬁrst AHCT for MM and
number of newly diagnosed cases in the period of interest. Because the
scope of the present work is disparity more than underutilization itself, and
to avoid possible errors intrinsic to the correction factor, we chose to work
with the concept of relative utilization ratio (RUR). We arrived at RUR for
each category of interest by dividing the apparent rate of utilization for a
given category by the utilization rate for the entire population. The RUR was
calculated for each sex, REC, and age. The population of women is slightly
older than the population of men with MM. RECs also have a diverse age
structure [12]. Therefore, we also compared RUR between RECs and between
sexes within a given category by adjusting the age structure of MM cases in
each category to match that of the most numerous categories (NHW men).
Statistics
We described continuous numerical variables by median and inter-
quartile range. Comparisons between proportions were performed using
chi-square test. All statistical analysis was performed utilizing SPSS (IBM
Corp. Released 2013. IBM SPSS Statistics forWindows, Version 22.0. Armonk,
NY). In all inference analyses, 2-sided P values of less than .05 were
considered to indicate statistical signiﬁcance.
RESULTS
We utilized data from 22,462 actual MM cases reported to
SEER (excluding 178 cases with unknown race) and 13,311
actual AHCT reported to CIBMTR. Table 1 displays the dis-
tribution of MM cases and AHCT cases by sex and REC after
calculation of the total United States’ numbers, along with
the median age for each subcategory. Median age at diag-
nosis of MM was higher in NHW than in any of the other
RECs (P¼ .0002). In all RECs, the age at diagnosis was older in
women than in men.
Disparity
Both the unadjusted and the age-adjusted RURs are dis-
played in Table 2 for each sex and REC. Higher utilization of
AHCT was detected in men among Hispanics but not among
NHB or Asians. Among NHW, the apparently higher RUR in
men becomes nonsigniﬁcant when RUR is adjusted for age
structure. This ﬁnding suggests that the higher AHCT utili-
zation in NHWmen than in NHWwomen is a function more
of younger age at diagnosis than sex.
We subsequently aggregated data from both sexes to
compare AHCT utilization among the RECs. Adjusted RUR
was 1.17 (95% conﬁdence interval [CI], 1.15 to 1.19) among
NHW, higher than in NHB (.69; 95% CI, .67 to .72; P < .0002),
Hispanics (.64; 95% CI, .60 to .69; P < .002), and Asians (.65;
95% CI, .58 to .73; P < .0002). In fact, Figure 1 displays RUR as
a function of age and sex for all RECs, making clear the
highest AHCT utilization among NHW. It is also obvious that
AHCT declines with age in all RECs for both men and women,
with the decline becoming very pronounced after the age of
55 years.
Even though the reasons for racial and ethnic disparity in
transplantation access are unknown, we performed an
exploratory analysis in an attempt to recognize possible links
between health care insurance and REC. InsuranceAdjusted RUR
Men Women P
1.18 (1.16-1.20) 1.16 (1.13-1.18) .23
.70 (.66-.74) .69 (.65-.73) .89
.72 (.66-.79) .56 (.50-.63) .007
.66 (.56-.77) .64 (.54-.76) .81
1.02 (1.01-1.04) .97 (.98-.99) <.0002
Figure 1. Relative utilization ratio for AHCT in MM according to sex and age in the different race and ethnicity categories.
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onward. We found that only 3.1% of the NHW patients with
MM younger than 65 were identiﬁed as uninsured versus
8.1% of NHB, 11.9% of Hispanics, and 3.2% of Asians (P <
.0001). Along the same lines, Medicaid was the primary in-
surance for 7.1% of NHW, versus 17.8% of NHB, 28% of His-
panics, and 13.5% of Asians (P < .001).Effect of Disparities in AHCT Activity
We subsequently aimed to understand the impact of
disparities in the overall AHCT utilization and trans-
plantation volumes for MM. This was obtained by simulating
AHCT numbers for the subcategory of interest when the
utilization rates of a reference subcategory are applied to its
MM population. Therefore, for estimation of underutilization
due to sex disparity, utilization in menwas used as reference.
For estimation of underutilization due to race, NHWwas the
reference group.
We found that 1.3% of potential AHCT procedures are
unrealized because of sex disparity. This reaches 10.4%
among Hispanics and is lower among Asians and NHB
(Figure 2A).
A much bigger impact can be attributed to race and
ethnicity disparity that prevents 13.8% of AHCT procedures,
with a much greater impact seen in NHB, Hispanics, and
Asians (Figure 2B).
The impact of age disparity is more complex. Comorbid-
ities impeding AHCT tend to becomemore commonwith age
and there are very limited data supporting AHCT for the
treatment of MM in individuals older than 75. Therefore,
some decline in AHCT utilizationwith age is to be expected. It
is known that the median age of MM patients pursuing AHCT
continues to increase [11]. We estimated the potential futureimpact of this increase by calculating transplantation vol-
umes when the current utilization rate for a given age is
replaced by that of a younger age. For example, to calculate
the impact of 2-year increase in age at AHCT, we projected
transplantation volume by applying to a population of a
certain age (eg, 70 years) the current utilization rate of age
minus 2 (in this example, 68 years). The impact of age
disparity in AHCT utilization can be seen in Figure 2C. A 2-
year increase in age of the AHCT population would lead to
a 12% increase, whereas a 5-year increasewould lead to a 32%
in the volume of AHCT for MM. Because RECs have diverse
age structures, they are affected differently by the aging of
the AHCT population. A larger effect would be seen among
NHW and Asians, whereas a smaller effect would be seen
among NHB and Hispanics.DISCUSSION
Age and sex disparities in access to AHCT for treatment of
MM have been described before [9,10]. A prior publication
from the CIBMTR covering autologous transplantation activity
in the United States from 1997 to 2002 found that Whites
weremore likely than Blacks (odds ratio,1.72) andmales were
more likely than females (odds ratio, 1.1) to undergo AHCT for
MM [9]. Importantly, by performing sensitivity analysis, that
study found that selective under-reporting of transplantations
performed in ethnic minorities, in addition to being unlikely,
is not expected to affect the main conclusion. Similar dispar-
ities were seen in transplantation utilization for other hema-
tologic disorders. That study, however, did not address
transplantation utilization in Hispanic and Asians or sex dis-
parities in access within each speciﬁc race.
More recently, Al-Hamadani et al. [10] used data from
the National Cancer Data Base to identify socio-geo-
Figure 2. Estimated impact of sex (panel A) and race and ethnicity disparities (panel B) in AHCT activity. Potential impact in volume of AHCT for MM resulting from
the increase in the age of patients undergoing transplantation (panel C).
L.J. Costa et al. / Biol Blood Marrow Transplant 21 (2015) 701e706704demographic factors associated with the utilization of AHCT
for upfront treatment of MM. This study identiﬁed Black
and Asian races, Hispanic ethnicity, older age, low neigh-
borhood income or education, residence in a metro area,and no or unknown medical insurance as factors associated
with lower likelihood of use of upfront AHCT. Of interest,
sex was not an independent factor associated with use of
AHCT.
L.J. Costa et al. / Biol Blood Marrow Transplant 21 (2015) 701e706 705The present study explores, in detail, AHCT utilization in
all main RECs, addresses the differential impact of sex in
transplantation utilization among the different RECs, and
provides detailed information on the effect of age in AHCT
within each REC. Moreover, we estimated the impact of each
recognized disparity in the overall volume of AHCT for MM.
Unfortunately, because information linking transplantation
and patient’s place of residence is missing from the CIBMTR
database, it was not possible to conﬁrm the recently found
underutilization of AHCT for MM in the Northeast [10].
Our study conﬁrms the prior demonstration of profound
underutilization of AHCT among Black patients with MM.
However, underutilization almost to the same magnitude can
be seen among Hispanics and Asians. Unfortunately, the da-
tabases used for the study do not provide an explanation for
the strong link between REC and AHCT utilization. Recent
work using data from the National Cancer Data Base demon-
strated that racial disparity in access to AHCT persists even
when adjusted for income and education [10]. It is possible
that patient and physician bias play a role in the decision to
pursue transplantation. Another possibility is that income and
educational differenceswithin a given geographic areamay be
linked to both race and transplantation utilization, and these
differences are not captured when those variables are
analyzed collectively instead of at the individual patient level.
Our data also suggest that lack of health care insurance or
coverage under Medicaid may be linked to the lower AHCT
utilization amongNHB andHispanics, as 2 studies have shown
lower utilization of AHCT among Medicaid beneﬁciaries
[10,14]. However, it is unlikely that insurance plays a major
role among Asians, as the pattern of insurance coverage was
very similar to that seen in NHW.
Prior studies addressing disparity in access to AHCT have
not explored the interaction between sex and REC or have
not found such an interaction [9,10]. We found, however, that
the underutilization of AHCT amongwomenwith MM is only
signiﬁcant among Hispanics for reasons that are unknown.
Lastly, we estimated the impact of access disparities in
AHCT volumes. Racial disparity itself prevents approximately
1 in 7 potential AHCT for MM. Among NHB, Hispanics, and
Asians, almost one half of the potential transplantations do
not occur because of disparity in access. In addition to the
possible detrimental effect on outcome from the lack of
transplantation therapy, it is also possible that trans-
plantation serves as a surrogate for more advanced tertiary
level care. Barriers preventing minority patients from
accessing transplantation may be the same as those pre-
venting them from accessing advanced supportive care,
novel agents, clinical trials, and expert consultation, with
potential further impairment of outcomes.
As the ﬁeld evolves, age is no longer considered an ab-
solute barrier to transplantation in general [15], although
only 1 positive randomized trial comparing transplantation
and nontransplantation therapy in MM included patients
older than 65 [16] and 1 study with patients 65 to 75 years
old failed to show advantage of “reduced-intensity” AHCT
over conventional therapy [17]. Age disparity is, however, the
main contributor to AHCT underutilization in MM. As
demonstrated in Figure 2, the evolving inclusion of AHCTas a
viable therapy for older patients will sharply increase
transplantation volumes at a rate of approximately 6% for
each year of increase in the median age of AHCT patients.
Even though this is a positive trend, it will present a further
challenge because of the anticipated workforce shortage in
blood and marrow transplantation [18].In summary, race and ethnicity disparity greatly affects
AHCT utilization for management of MM in the United States.
Sex disparity plays a much lesser role, except among His-
panics. The profound age disparity is decreasing over time
and will likely continue to drive major increase of AHCT
activity.
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